Market revenue in 2023 | USD 1.2 million |
Market revenue in 2030 | USD 3.5 million |
Growth rate | 16.8% (CAGR from 2023 to 2030) |
Largest segment | Neurology |
Fastest growing segment | Orthopedic |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Dental, Orthopedic, Neurology |
Key market players worldwide | GlaxoSmithKline, Hewlett Packard Enterprise Co, Merck KGaA, AstraZeneca PLC, Aprecia Pharmaceuticals, Extend Biosciences, BioDuro, Affini-T Therapeutics, Osmotica Pharmaceutical, FabRx, Cycle Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to 3d printed drugs market will help companies and investors design strategic landscapes.
Neurology was the largest segment with a revenue share of 50% in 2023. Horizon Databook has segmented the Australia 3d printed drugs market based on dental, orthopedic, neurology covering the revenue growth of each sub-segment from 2018 to 2030.
The market for 3D printed drugs in Australia has been steadily growing due to various factors. One of the key factors responsible for this growth is the increasing demand for innovative solutions in healthcare and biotechnology. As the population ages and healthcare needs become more complex, there is a growing interest in developing 3D printed drugs.
Australia is witnessing growth in its 3D printed drugs market, driven by a focus on personalized medicine and the country's well-established medical & research infrastructure. Australia's innovative and research oriented environment, along with significant government support for healthcare advancements, is boosting the adoption of 3D printing in drug production.
However, the regulations for 3D printed medicines are under development, which is expected to hinder growth in the foreseeable future. According to an article published in The Conversation in June 2023, the Therapeutic Goods Administration is expected to regulate 3D printed medicines in the country; however, regulators are yet to show any progress in this technology.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia 3d printed drugs market , including forecasts for subscribers. This country databook contains high-level insights into Australia 3d printed drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account